Put Options

10 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2022

Oct 25, 2022

BUY
$1.88 - $2.88 $1,316 - $2,016
700 New
700 $0
Q1 2022

Apr 14, 2022

SELL
$2.42 - $3.98 $46,222 - $76,018
-19,100 Reduced 89.25%
2,300 $0
Q4 2021

Jan 18, 2022

BUY
$3.11 - $4.61 $65,932 - $97,732
21,200 Added 10600.0%
21,400 $19,000
Q3 2021

Oct 26, 2021

BUY
$2.65 - $4.62 $265 - $462
100 Added 100.0%
200 $0
Q2 2021

Jul 19, 2021

BUY
$2.5 - $3.51 $250 - $351
100 New
100 $0
Q2 2019

Aug 09, 2019

SELL
$1.46 - $4.44 $8,760 - $26,640
-6,000 Closed
0 $0
Q1 2019

May 10, 2019

SELL
$3.41 - $4.57 $6,820 - $9,140
-2,000 Reduced 25.0%
6,000 $10,000
Q3 2018

Nov 07, 2018

BUY
$7.85 - $12.35 $58,090 - $91,390
7,400 Added 1233.33%
8,000 $3,000
Q1 2018

May 11, 2018

BUY
$4.4 - $6.05 $2,200 - $3,025
500 Added 500.0%
600 $0
Q3 2017

Oct 17, 2017

BUY
$3.4 - $7.0 $340 - $700
100
100 $0

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.